Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

NCT07246096 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Autoimmune Diseases
Systemic Lupus Erythematosus
Systemic Sclerosis
Primary Sjögren Syndrome
Rheumatoid Arthritis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions

BIOLOGICAL: anti-CD19/BCMA U CAR T cells

Sponsor

Changhai Hospital

Collaborators

[object Object]